Search Legislation

Misuse of Drugs Act 1971

What Version

 Help about what version

Advanced Features

 Help about advanced features

Changes to legislation:

There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

Section 2.

SCHEDULE 2E+W+S+N.I. Controlled Drugs

Part IE+W+S+N.I. Class A Drugs

1The following substances and products, namely:—E+W+S+N.I.

[F1(a)]

  • Acetorphine.

  • [F2Alfentanil.]

  • Allylprodine.

  • Alphacetylmethadol.

  • Alphameprodine.

  • Alphamethadol.

  • Alphaprodine.

  • Anileridine.

  • Benzethidine.

  • Benzylmorphine (3-benzylmorphine).

  • Betacetylmethadol.

  • Betameprodine.

  • Betamethadol.

  • Betaprodine.

  • Bezitramide.

  • Bufotenine.

  • F3...

  • F4...

  • [F5Carfentanil.]

  • Clonitazene.

  • Coca leaf.

  • Cocaine.

  • Desomorphine.

  • Dextromoramide.

  • Diamorphine.

  • Diampromide.

  • Diethylthiambutene.

  • [F6Difenoxin (1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid).]

  • DihydrocodeinoneO-carboxymethyloxime.

  • [F7Dihydroetorphine]

  • Dimenoxadole.

  • Dimepheptanol.

  • Dimethylthiambutene.

  • Dioxaphetyl butyrate.

  • Diphenoxylate.

  • Dipipanone.

  • [F8Drotebanol (3,4-dimethoxy-17-methylmorphinan-6b, 14-diol).]

  • Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine.

  • Ethylmethylthiambutene.

  • [F2Eticyclidine.]

  • Etonitazene.

  • Etorphine.

  • Etoxeridine.

  • [F9Etryptamine]

  • Fentanyl.

  • [F10Fungus (of any kind) which contains psilocin or an ester of psilocin.]

  • Furethidine.

  • Hydrocodone.

  • Hydromorphinol.

  • Hydromorphone.

  • Hydroxypethidine.

  • Isomethadone.

  • Ketobemidone.

  • Levomethorphan.

  • Levomoramide.

  • Levophenacylmorphan.

  • Levorphanol.

  • [F5Lofentanil]

  • Lysergamide.

  • Lysergide and otherN-alkyl derivatives of lysergamide.

  • Mescaline.

  • Metazocine.

  • Methadone.

  • Methadyl acetate.

  • [F11Methylamphetamine]

  • Methyldesorphine.

  • Methyldihydromorphine (6-methyldihydromorphine).

  • Metopon.

  • Morpheridine.

  • Morphine.

  • Morphine methobromide, morphineN-oxide and other pentavalent nitrogen morphine derivatives.

  • Myrophine.

  • F12. . .

  • Nicomorphine (3,6-dinicotinoylmorphine).

  • Noracymethadol.

  • Norlevorphanol.

  • Normethadone.

  • Normorphine.

  • Norpipanone.

  • Opium, whether raw, prepared or medicinal.

  • Oxycodone.

  • Oxymorphone.

  • Pethidine.

  • Phenadoxone.

  • Phenampromide.

  • Phenazocine.

  • [F13Phencyclidine.]

  • Phenomorphan.

  • Phenoperidine.

  • Piminodine.

  • Piritramide.

  • Poppy-straw and concentrate of poppy-straw.

  • Proheptazine.

  • Properidine (1-methyl-4-phenyl-piperidine-4-carboxylic acid isopropyl ester).

  • Psilocin.

  • Racemethorphan.

  • Racemoramide.

  • Racemorphan.

  • [F14Remifentanil]

  • [F2Rolicyclidine.]

  • [F15Sufentanil.]

  • [F16Tapentadol.]

  • [F2Tenocylidine.]

  • Thebacon.

  • Thebaine.

  • [F15Tilidate.]

  • Trimeperidine.

  • [(6aR,9R)-4-acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ALD-52).]

  • [F17(6aR,9R)-4-acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ALD-52).]

  • [F184-Bromo-2,5-dimethoxy-a-methylphenethylamine].

  • 4-Cyano-2-dimethylamino-4,4-diphenylbutane.

  • 4-Cyano-1-methyl-4-phenyl-piperidine.

  • [F191-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45).]

  • [F203,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921);

  • (6aR,9R) R,9 R)- N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (AL-LAD);

  • (6aR,9R) R,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ETH-LAD);

  • (6aR,9R)R,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (PRO-LAD).]

  • N,N-Diethyltryptamine.

  • [F212,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg]quinolin-9-yl}methanone (LSZ).]

  • N,N-Dimethyltryptamine.

  • 2,5-Dimethoxy-a,4-dimethylphenethylamine.

  • [F22N-Hydroxy-tenamphetamine.]

  • 1-Methyl-4-phenylpiperidine-4-carboxylic acid.

  • 2-Methyl-3-morpholino-1, 1-diphenylpropanecarboxylic acid.

  • [F234-Methyl-aminorex]

  • [F244-Methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4’-DMAR).]

  • 4-Phenylpiperidine-4-carboxylic acid ethyl ester.

[F25(b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say—

(i)by substitution at the nitrogen atom of the sidechain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;

(ii)by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;

(iii)by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents;

(iv)by substitution at the 2-position of the tryptamine ring system with an alkyl substituent;]

[F26(ba)the following phenethylamine derivatives, namely:—

  • Allyl( a -methyl-3,4-methylenedioxyphenethyl)amine

  • 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol

  • 2-Amino-1-(3,4-dimethoxyphenyl)ethanol

  • Benzyl( a -methyl-3,4-methylenedioxyphenethyl)amine

  • 4-Bromo- b ,2,5-trimethoxyphenethylamine

  • N -(4- sec -Butylthio-2,5-dimethoxyphenethyl)hydroxylamine

  • Cyclopropylmethyl( a -methyl-3,4-methylenedioxyphenethyl)amine

  • 2-(4,7-Dimethoxy-2,3-dihydro-1 H -indan-5-yl)ethylamine

  • 2-(4,7-Dimethoxy-2,3-dihydro-1 H -indan-5-yl)-1-methylethylamine

  • 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine

  • 2-(1,4-Dimethoxy-2-naphthyl)ethylamine

  • 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine

  • N -(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine

  • 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine

  • 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine

  • a , a -Dimethyl-3,4-methylenedioxyphenethylamine

  • a , a -Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine

  • Dimethyl( a -methyl-3,4-methylenedioxyphenethyl)amine

  • N -(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine

  • 4-Iodo-2,5-dimethoxy- a -methylphenethyl(dimethyl)amine

  • 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine

  • 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine

  • 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[ b ]furan-6-yl)-1-methylethylamine

  • 2-Methoxyethyl( a -methyl-3,4-methylenedioxyphenethyl)amine

  • 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[ b ]furan-6-yl)-1-methylethylamine

  • b -Methoxy-3,4-methylenedioxyphenethylamine

  • 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine

  • 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine

  • 2-( a -Methyl-3,4-methylenedioxyphenethylamino)ethanol

  • a -Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine

  • N -Methyl- N -( a -methyl-3,4-methylenedioxyphenethyl)hydroxylamine

  • O -Methyl- N -( a -methyl-3,4-methylenedioxyphenethyl)hydroxylamine

  • a -Methyl-4-(methylthio)phenethylamine

  • b ,3,4,5-Tetramethoxyphenethylamine

  • b ,2,5-Trimethoxy-4-methylphenethylamine; ]

[F27(c) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine an N -alkylphenethylamine,a-methylphenethylamine, an N -alkyl-a-methylphenethylamine,a-ethylphenethylamine, or an N -alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents. ]

[F28(d)any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from fentanyl by modification in any of the following ways, that is to say,

(i)by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;

(ii)by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;

(iii)by substitution in the piperidine ring with alkyl or alkenyl groups;

(iv)by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;

(v)by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;

(vi)by replacement of the N-propionyl group by another acyl group;

(e)any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from pethidine by modification in any of the following ways, that is to say,

(i)by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;

(ii)by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;

(iii)by substitution in the 4-phenyl ring wiith alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;

(iv)by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;

(v)by formation of an N-oxide or of a quaternary base.]

[F29(f)any compound (not being benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine) structurally derived from mescaline, 4-bromo-2,5-dimethoxy-α-methylphenethylamine, 2,5-dimethoxy-α,4-dimethylphenethylamine, N-hydroxytenamphetamine, or a compound specified in sub-paragraph (ba) or (c) above, by substitution at the nitrogen atom of the amino group with a benzyl substituent, whether or not substituted in the phenyl ring of the benzyl group to any extent.]

Annotations: Help about Annotation
Close

Annotations are used to give authority for changes and other effects on the legislation you are viewing and to convey editorial information. They appear at the foot of the relevant provision or under the associated heading. Annotations are categorised by annotation type, such as F-notes for textual amendments and I-notes for commencement information (a full list can be found in the Editorial Practice Guide). Each annotation is identified by a sequential reference number. For F-notes, M-notes and X-notes, the number also appears in bold superscript at the relevant location in the text. All annotations contain links to the affecting legislation.

Amendments (Textual)

F1"(a)" inserted by S.I. 1977/1243, art. 3(a)

F2Word inserted by S.I. 1984/859, art. 2(2)

F5Word inserted by S.I. 1986/2230, art. 2(2)(a)

F6Word inserted by S.I. 1975/421, art. 3

F7Word in Sch. 2 Pt. 1 para. 1(a) inserted (1.7.2003) by The Misuse of Drugs Act 1971 (Modification) Order 2003 (S.I 2003 /1243), {art. 2(2)(a)}

F8Word inserted by S.I. 1973/771, art. 2

F9Word in Sch. 2 Pt. I para. 1(a) inserted (1.5.1998) by S.I. 1998/750, art. 2(2)

F10Words in Sch. 2 Pt. 1 para. 1 inserted (18.7.2005) by Drugs Act 2005 (2005 c. 17), s. 21

F11Word in Sch. 2 Pt. 1 para. 1(a) inserted (18.1.2007) by The Misuse of Drugs Act 1971 (Amendment) Order 2006 (S.I.2006/3331), art. 2(1)

F12Words repealed by S.I. 1973/771, art. 2

F13Word inserted by S.I. 1979/299, art. 2

F14Word in Sch. 2 Pt. 1 para. 1(a) inserted (1.7.2003) by The Misuse of Drugs Act 1971 (Modification) Order 2003 (S.I 2003 /1243), {art. 2(2)(b)}

F15Word inserted by S.I. 1983/765, art. 2(a)

F16Word in Sch. 2 Pt. 1 para. 1(a) inserted (28.3.2011) by The Misuse of Drugs Act 1971 (Amendment) Order 2011 (S.I. 2011/744), arts. 1(1), 2

F18Words inserted by S.I. 1975/421, art. 3

F19Words in Sch. 2 Pt. 1 para. 1(a) inserted (11.3.2015) by The Misuse of Drugs Act 1971 (Amendment) Order 2015 (S.I. 2015/215), art. 3(a)

F24Words in Sch. 2 Pt. 1 para. 1(a) inserted (11.3.2015) by The Misuse of Drugs Act 1971 (Amendment) Order 2015 (S.I. 2015/215), art. 3(b)

F27Sch. 2 Pt. I para. 1(b)(c) added by S.I. 1977/1243, art. 3(b)

F28Sch. 2 Pt. I para. 1(d)(e) added by S.I. 1986/2230, art. 2(2)(b)

2Any stereoisomeric form of a substance for the time being specified in paragraph 1 above not being dextromethorphan or dextrorphan.E+W+S+N.I.

3Any ester or ether of a substance for the time being specified in paragraph 1 or 2 above [F30not being a substance for the time being specified in Part II of this Schedule].E+W+S+N.I.

Annotations: Help about Annotation
Close

Annotations are used to give authority for changes and other effects on the legislation you are viewing and to convey editorial information. They appear at the foot of the relevant provision or under the associated heading. Annotations are categorised by annotation type, such as F-notes for textual amendments and I-notes for commencement information (a full list can be found in the Editorial Practice Guide). Each annotation is identified by a sequential reference number. For F-notes, M-notes and X-notes, the number also appears in bold superscript at the relevant location in the text. All annotations contain links to the affecting legislation.

Amendments (Textual)

F30Words inserted by S.I. 1973/771, art. 2

4Any salt of a substance for the time being specified in any of paragraphs 1 to 3 above.E+W+S+N.I.

5Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 4 above.E+W+S+N.I.

6Any preparation designed for administration by injection which includes a substance or product for the time being specified in any of paragraphs 1 to 3 of Part II of this Schedule.E+W+S+N.I.

Part IIE+W+S+N.I. Class B Drugs

1The following substances and products, namely:—E+W+S+N.I.

[F31(a)]

  • Acetyldihydrocodeine.

  • Amphetamine.

  • [F32Cannabinol]

  • [F32Cannabinol derivatives]

  • [F32Cannabis and cannabis resin]

  • F33...

  • Codeine.

  • F34. . .

  • Dihydrocodeine.

  • Ethylmorphine (3-ethylmorphine).

  • [F35Glutethimide.]

  • [F36Ketamine.]

  • [F35Lefetamine.]

  • [F37Lisdexamphetamine.]

  • [F38Mecloqualone.]

  • [F38Methaqualone.]

  • [F39Methcathinone]

  • F40...

  • F41...

  • [F42a-Methylphenethylhydroxylamine]

  • Methylphenidate.

  • [F38Methylphenobarbitone.]

  • Nicocodine.

  • [F43Nicodicodine (6-nicotinoyldihydrocodeine).]

  • Norcodeine.

  • [F44Pentazocine.]

  • Phenmetrazine.

  • Pholcodine.

  • [F45Propiram.]

  • [F39Zipeprol]

  • [F462-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol.]

[F47(aa)Any compound (not being bupropion, cathinone, diethylpropion, pyrovalerone or a compound for the time being specified in sub–paragraph (a) above) structurally derived from 2–amino–1–phenyl–1–propanone by modification in any of the following ways, that is to say,

(i)by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;

(ii)by substitution at the 3–position with an alkyl substituent;

(iii)by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.]

[F48(ab)Any compound structurally derived from 2–aminopropan–1–one by substitution at the 1-position with any monocyclic, or fused‑polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say,

(i)by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;

(ii)by substitution at the 3–position with an alkyl substituent;

(iii)by substitution at the 2‑amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.]

[F49(ac)Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group, whether or not the compound is further modified in any of the following ways, that is to say,

(i)by substitution in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or halide groups;

(ii)by substitution at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxy group;

(iii)by substitution at the ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group.]

[F31(b)any 5,5 disubstituted barbituric acid.]

[F50(c)[2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone.

  • [9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate.

  • [9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate.

  • 9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol.

  • Any compound structurally derived from 3–(1–naphthoyl)indole, 3-(2-naphthoyl) indole, 1H–indol–3–yl–(1–naphthyl)methane or 1H-indol-3-yl-(2-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

  • Any compound structurally derived from 3–(1–naphthoyl)pyrrole or 3-(2-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

  • Any compound structurally derived from 1–(1–naphthylmethylene)indene or 1-(2-naphthylmethylene)indene by substitution at the 3–position of the indene ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.

  • Nabilone.

  • Any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

  • Any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.

  • Any compound structurally derived from 3-benzoylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

  • Any compound structurally derived from 3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent.

  • Any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent.

[F51(ca)any compound (not being clonitazene, etonitazene, acemetacin, atorvastatin, bazedoxifene, indometacin, losartan, olmesartan, proglumetacin, telmisartan, viminol, zafirlukast or a compound for the time being specified in sub-paragraph (c) above) structurally related to 1-pentyl-3-(1-naphthoyl)indole (JWH-018), in that the four sub-structures, that is to say the indole ring, the pentyl substituent, the methanone linking group and the naphthyl ring, are linked together in a similar manner, whether or not any of the sub-structures have been modified, and whether or not substituted in any of the linked sub-structures with one or more univalent substituents and, where any of the sub-structures have been modified, the modifications of the sub-structures are limited to any of the following, that is to say—

(i)replacement of the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole, benzimidazole, pyrrolo[2,3-b]pyridine, pyrrolo[3,2-c]pyridine or pyrazolo[3,4‑b]pyridine;

(ii)replacement of the pentyl substituent with alkyl, alkenyl, benzyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, 2-(4-morpholinyl)ethyl or (tetrahydropyran-4-yl)methyl;

(iii)replacement of the methanone linking group with an ethanone, carboxamide, carboxylate, methylene bridge or methine group;

(iv)replacement of the 1-naphthyl ring with 2-naphthyl, phenyl, benzyl, adamantyl, cycloalkyl, cycloalkylmethyl, cycloalkylethyl, bicyclo[2.2.1]heptanyl, 1,2,3,4-tetrahydronaphthyl, quinolinyl, isoquinolinyl, 1-amino-1-oxopropan-2-yl, 1‑hydroxy-1-oxopropan-2-yl, piperidinyl, morpholinyl, pyrrolidinyl, tetrahydropyranyl or piperazinyl.]

(d)1-Phenylcyclohexylamine or any compound (not being ketamine, tiletamine or a compound for the time being specified in paragraph 1(a) of Part 1 of this Schedule) structurally derived from 1-phenylcyclohexylamine or 2-amino-2-phenylcyclohexanone by modification in any of the following ways, that is to say,

(i)by substitution at the nitrogen atom to any extent by alkyl, alkenyl or hydroxyalkyl groups, or replacement of the amino group with a 1-piperidyl, 1-pyrrolidyl or 1-azepyl group, whether or not the nitrogen containing ring is further substituted by one or more alkyl groups;

(ii)by substitution in the phenyl ring to any extent by amino, alkyl, hydroxy, alkoxy or halide substituents, whether or not further substituted in the phenyl ring to any extent;

(iii)by substitution in the cyclohexyl or cyclohexanone ring by one or more alkyl substituents;

(iv)by replacement of the phenyl ring with a thienyl ring.]

[F52(e)Any compound (not being a compound for the time being specified in paragraph 1(ba) of Part 1 of this Schedule) structurally derived from 1-benzofuran, 2,3-dihydro-1-benzofuran, 1H-indole, indoline, 1H-indene, or indane by substitution in the 6-membered ring with a 2-ethylamino substituent whether or not further substituted in the ring system to any extent with alkyl, alkoxy, halide or haloalkyl substituents and whether or not substituted in the ethylamino side-chain with one or more alkyl substituents.]

Annotations: Help about Annotation
Close

Annotations are used to give authority for changes and other effects on the legislation you are viewing and to convey editorial information. They appear at the foot of the relevant provision or under the associated heading. Annotations are categorised by annotation type, such as F-notes for textual amendments and I-notes for commencement information (a full list can be found in the Editorial Practice Guide). Each annotation is identified by a sequential reference number. For F-notes, M-notes and X-notes, the number also appears in bold superscript at the relevant location in the text. All annotations contain links to the affecting legislation.

Amendments (Textual)

F31Sch. 2 Pt. 2 para. 1(b) added by S.I. 1984/859, art. 2(3)

F32Words in Sch. 2 Pt. 2 para. 1(a) inserted (26.1.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), art. 2(2)(a)

F33Words in Sch. 2 Pt. 2 para. 1(a) deleted (29.1.2004) by The Misuse of Drugs Act 1971 (Modification) (No. 2) Order 2003 (S.I. 2003/3201), art. 2(3)

F36Word in Sch. 2 Pt. 2 para. 1(a) inserted (10.6.2014) by The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014 (S.I. 2014/1106), art. 4(a)(i)

F37Word in Sch. 2 Pt. 2 para. 1(a) inserted (10.6.2014) by The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014 (S.I. 2014/1106), art. 4(a)(ii)

F38Word inserted by S.I. 1984/859, art. 2(3)

F39Words in Sch. 2 Pt. 2 para. 1(a) inserted (1.5.1998) by S.I. 1998/750, art. 2(3)

F40Word in Sch. 2 Pt. 2 para. 1(a) omitted (28.3.2011) by virtue of The Misuse of Drugs Act 1971 (Amendment) Order 2011 (S.I. 2011/744), arts. 1(1), 3

F41Word in Sch. 2 Pt. 2 para. 1(a) repealed (18.1.2007) by The Misuse of Drugs Act 1971 (Amendment) Order 2006 (S.I.2006/3331), art. 2(2)

F42Word in Sch. 2 Pt. 2 para. 1(a) inserted (1.2.2002) by S.I. 2001/3932, art. 2(3)

F43Words inserted by S.I. 1973/771, art. 2

F45Word inserted by S.I. 1973/771, art. 2

F46Words in Sch. 2 Pt. 2 para. 1(a) inserted (26.2.2013) by The Misuse of Drugs Act 1971 (Amendment) Order 2013 (S.I. 2013/239), art. 3

F47Sch. 2 Pt. 2 para. 1(aa) inserted (16.4.2010) by The Misuse of Drugs Act 1971 (Amendment) Order 2010 (S.I. 2010/1207), art. 2(b)

F49Sch. 2 Pt. 2 para. 1(ac) inserted (13.6.2012) by The Misuse of Drugs Act 1971 (Amendment) Order 2012 (S.I. 2012/1390), art. 2(a)

F50Sch. 2 Pt. 2 para. 1(c)(d) substituted (26.2.2013) for Sch. 2 Pt. 2 para. 1(c) by The Misuse of Drugs Act 1971 (Amendment) Order 2013 (S.I. 2013/239), art. 4

F51Sch. 2 Pt. 2 para. 1(ca) inserted (14.12.2016) by The Misuse of Drugs Act 1971 (Amendment) Order 2016 (S.I. 2016/1109), arts. 1, 3(a)

F52Sch. 2 Pt. 2 para. 1(e) inserted (10.6.2014) by The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014 (S.I. 2014/1106), art. 4(b)

2Any stereoisomeric form of a substance for the time being specified in paragraph 1 of this Part of this Schedule.E+W+S+N.I.

[F532A.Any ester or ether of cannabinol or of a cannabinol derivative [F54or of a substance for the time being specified in [F55paragraph 1(ac), [F56(c), (ca)] or (d)] of this Part of this Schedule.] .]E+W+S+N.I.

Annotations: Help about Annotation
Close

Annotations are used to give authority for changes and other effects on the legislation you are viewing and to convey editorial information. They appear at the foot of the relevant provision or under the associated heading. Annotations are categorised by annotation type, such as F-notes for textual amendments and I-notes for commencement information (a full list can be found in the Editorial Practice Guide). Each annotation is identified by a sequential reference number. For F-notes, M-notes and X-notes, the number also appears in bold superscript at the relevant location in the text. All annotations contain links to the affecting legislation.

Amendments (Textual)

F54Words in Sch. 2 Pt. 2 para. 2A inserted (23.12.2009) by Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), arts. 1, 2(2)(b)

F55Words in Sch. 2 Pt. 2 para. 2A substituted (26.2.2013) by The Misuse of Drugs Act 1971 (Amendment) Order 2013 (S.I. 2013/239), art. 5

F56Words in Sch. 2 Pt. 2 para. 2A substituted (14.12.2016) by The Misuse of Drugs Act 1971 (Amendment) Order 2016 (S.I. 2016/1109), arts. 1. 3(b)

3Any salt of a substance for the time being specified in paragraph 1 [F57, 2 or 2A] of this Part of this Schedule.E+W+S+N.I.

Annotations: Help about Annotation
Close

Annotations are used to give authority for changes and other effects on the legislation you are viewing and to convey editorial information. They appear at the foot of the relevant provision or under the associated heading. Annotations are categorised by annotation type, such as F-notes for textual amendments and I-notes for commencement information (a full list can be found in the Editorial Practice Guide). Each annotation is identified by a sequential reference number. For F-notes, M-notes and X-notes, the number also appears in bold superscript at the relevant location in the text. All annotations contain links to the affecting legislation.

Amendments (Textual)

F57Words in Sch. 2 Pt. 2 para. 3 substituted ( 26.1.2009 ) by The Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), art. 2(2)(c)

4Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 3 of this Part of this Schedule, not being a preparation falling within paragraph 6 of Part I of this Schedule.E+W+S+N.I.

Part IIIE+W+S+N.I. Class C Drugs

1The following substances, namely:—E+W+S+N.I.

[F58(a)]

  • [F59Alprazolam.]

  • [F60Amineptine]

  • [F61Aminorex]

  • [F59Bromazepam.]

  • [F627-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one.]

  • Benzphetamine.

  • [F61Brotizolam]

  • [F63Buprenorphine]

  • [F59Camazepam.]

  • F64...

  • F65...

  • F66...

  • [F67Cathine.]

  • [F67Cathinone.]

  • [F59Chlordiazepoxide.]

  • Chlorphentermine.

  • [F59Clobazam.]

  • [F59Clorazepic acid.]

  • [F59Clonazepam.]

  • [F59Clotiazepam.]

  • [F59Cloxazolam.]

  • [F59Delorazepam.]

  • [F68Dextropropoxyphene.]

  • [F59Diazepam.]

  • [F69Diethylpropion.]

  • [F59Estazolam.]

  • [F59Ethchlorvynol.]

  • [F59Ethinamate.]

  • [F59Ethyl loflazepate.]

  • [F67Fencamfamin.]

  • [F67Fenethylline.]

  • [F67Fenproporex.]

  • [F59Fludiazepam.]

  • [F59Flunitrazepam.]

  • [F59Flurazepam.]

  • [F70Gamma–butyrolactone]

  • [F59Halazepam.]

  • [F59Haloxazolam.]

  • [F714-Hydroxy-n-butyric acid]

  • F72...

  • [F59Ketazolam.]

  • [F73Khat.]

  • [F59Loprazolam.]

  • [F59Lorazepam.]

  • [F59Lormetazepam.]

  • [F59Mazindol.]

  • [F59Medazepam.]

  • [F67Mefenorex.]

  • F74. . .

  • Mephentermine.

  • [F59Meprobamate.]

  • [F61Mesocarb]

  • F75. . .

  • [F59Methyprylone.]

  • [F76Midazolam.]

  • [F59Nimetazepam.]

  • [F59Nitrazepam.]

  • [F59Nordazepam.]

  • [F59Oxazepam.]

  • [F59Oxazolam.]

  • [F77Pemoline.]

  • F74. . .

  • Phendimetrazine.

  • [F59Phentermine.]

  • [F59Pinazepam.]

  • F74. . .

  • F78...

  • [F59Prazepam.]

  • F74. . .

  • F79. . .

  • [F67Pyrovalerone.]

  • [F59Temazepam.]

  • [F59Tetrazepam.]

  • [F80Tramadol.]

  • [F59Triazolam.]

  • [F67N-Ethylamphetamine.]

  • [F81Zaleplon.]

  • [F82Zolpidem]

  • [F83Zopiclone.]

[F84(b)

  • [F855α–Androstane–3,17–diol.]

  • [F86Androst-4-ene-3,17-diol.]

  • [F871–Androstenediol.]

  • [F881–Androstenedione]

  • [F894-Androstene-3, 17-dione]

  • [F905–Androstenedione.]

  • [F895-Androstene-3, 17-diol]

  • Atamestane.

  • Bolandiol.

  • Bolasterone.

  • Bolazine.

  • Boldenone.

  • [F91Boldione.]

  • Bolenol.

  • Bolmantalate.

  • [F921,4–Butanediol.]

  • Calusterone.

  • 4-Chloromethandienone.

  • Clostebol.

  • [F93Danazol.]

  • [F94Desoxymethyltestosterone]

  • [F95Dienedione (estra-4, 9-diene-3,17-dione).]

  • Drostanolone.

  • Enestebol.

  • Epitiostanol.

  • Ethyloestrenol.

  • Fluoxymesterone.

  • Formebolone.

  • Furazabol.

  • [F96Gestrinone.]

  • [F973–Hydroxy–5α–androstan–17–one.]

  • Mebolazine.

  • Mepitiostane.

  • Mesabolone.

  • Mestanolone.

  • Mesterolone.

  • Methandienone.

  • Methandriol.

  • Methenolone.

  • Methyltestosterone.

  • Metribolone.

  • Mibolerone.

  • Nandrolone.

  • [F9819–Norandrostenedione.]

  • [F9919-Nor-4-Androstene-3, 17-dione]

  • [F10019–Norandrosterone.]

  • [F9919-Nor-5-Androstene-3, 17-diol]

  • Norboletone.

  • Norclostebol.

  • Norethandrolone.

  • [F10119–Noretiocholanolone.]

  • [F102Oripavine.]

  • Ovandrotone.

  • Oxabolone.

  • Oxandrolone.

  • Oxymesterone.

  • Oxymetholone.

  • [F103Pipradrol.]

  • Prasterone.

  • Propetandrol.

  • [F104Prostanozol]

  • Quinbolone.

  • Roxibolone.

  • Silandrone.

  • Stanolone.

  • Stanozolol.

  • Stenbolone.

  • Testosterone.

  • [F105Tetrahydrogestrinone.]

  • Thiomesterone.

  • Trenbolone.

(c)any compound (not being Trilostane or a compound for the time being specified in sub-paragraph (b) above) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say,

(i)by further substitution at position 17 by a methyl or ethyl group;

(ii)by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;

(iii)by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;

(iv)by fusion of ring A with a heterocyclic system;

[F106(ca )1–benzylpiperazine or any compound structurally derived from 1–benzylpiperazine or 1–phenylpiperazine by modification in any of the following ways—

(i)by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;

(ii)by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups.]

(d)any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in sub-paragraph (b) or described in sub-paragraph (c) above F107...;

(e)

  • Chorionic Gonadotrophin (HCG).

  • Clenbuterol.

  • Non-human chorionic gonadotrophin.

  • Somatotropin.

  • Somatrem.

  • Somatropin.]

  • [F108Zeranol.]

  • [F109Zilpaterol.]

Annotations: Help about Annotation
Close

Annotations are used to give authority for changes and other effects on the legislation you are viewing and to convey editorial information. They appear at the foot of the relevant provision or under the associated heading. Annotations are categorised by annotation type, such as F-notes for textual amendments and I-notes for commencement information (a full list can be found in the Editorial Practice Guide). Each annotation is identified by a sequential reference number. For F-notes, M-notes and X-notes, the number also appears in bold superscript at the relevant location in the text. All annotations contain links to the affecting legislation.

Amendments (Textual)

F58"(a)" inserted (1.9.1996) by S.I. 1996/1300, art. 2(2)(a)

F59Word inserted by S.I. 1985/1995, art. 2(3)

F60Word in Sch. 2 Pt. 3 para. 1(a) inserted (28.3.2011) by The Misuse of Drugs Act 1971 (Amendment) Order 2011 (S.I. 2011/744), arts. 1(1), 4

F61Words in Sch. 2 Pt. 3 para. 1(a) inserted (1.5.1998) by S.I. 1998/750, art. 2(4)

F62Words in Sch. 2 Pt. 3 para. 1(a) inserted (13.6.2012) by The Misuse of Drugs Act 1971 (Amendment) Order) 2012 (S.I. 2012/1390), art. 3(a)(ii)

F63Word inserted by S.I. 1989/1340, art. 2(a)

F64Word in Sch. 2 Pt. 3 para. 1(a) repealed (26.1.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), art. 2(3)(a)

F65Words in Sch. 2 Pt. 3 para. 1(a) repealed (26.1.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), art. 2(3)(a)

F66Words in Sch. 2 Pt. 3 para. 1(a) repealed (26.1.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), art. 2(3)(a)

F67Word inserted by S.I. 1986/2230, art. 2(3)

F68Word inserted by S.I. 1983/765, art. 2(a)

F69Word inserted by S.I. 1984/859, art. 2(4)(a)

F70Word in Sch. 2 Pt. 3 para. 1(a) inserted (23.12.2009 ) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(a)

F71Word in Sch. 2 Pt. 3 para. 1(a) inserted (1.7.2003) by The Misuse of Drugs Act 1971 (Modification) Order 2003 (S.I. 2003/1243), arts. 1, 2(3)(a)

F72Word in Sch. 2 Pt. 3 para. 1(a) omitted (10.6.2014) by virtue of The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014 (S.I. 2014/1106), art. 5(a)

F73Word in Sch. 2 Pt. 3 para. 1(a) inserted (24.6.2014) by The Misuse of Drugs Act 1971 (Amendment) Order 2014 (S.I. 2014/1352), art. 3

F74Words repealed by S.I. 1973/771, art. 2

F75Word repealed by S.I. 1984/859, art. 2(4)(a)

F76Word inserted by S.I. 1990/2589, art. 2(b)

F77Word inserted by S.I. 1989/1340, art. 2(b)

F78Word in Sch. 2 Pt. 3 para. 1(a) omitted (13.6.2012) by virtue of The Misuse of Drugs Act 1971 (Amendment) Order 2012 (S.I. 2012/1390), art. 3(a)(i)

F79Word in Sch. 2 Pt. 3 para.1 omitted (1.9.1995) by virtue of S.I. 1995/1966, art. 2

F82Word in Sch. 2 Pt. 3 para. 1(a) inserted (1.7.2003) by The Misuse of Drugs Act 1971 (Modification) Order 2003 (S.I. 2003/1243), arts. 1, 2(3)(b)

F84Sch. 2 Pt. 3 para. 1(b)-(e) added (1.9.1996) by S.I. 1996/1300, art. 2(2)(b)

F85Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(i)

F86Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(i)

F87Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(i)

F88Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(i)

F89Word in Sch. 2 Pt. 3 para. 1(b) inserted (1.7.2003) by The Misuse of Drugs Act 1971 (Modification) Order 2003 (S.I. 2003/1243), arts. 1, 2(4)(a)

F90Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(ii)

F91Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(iii)

F92Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(iv)

F93Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(v)

F94Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(v)

F95Words in Sch. 2 Pt. 3 para. 1(b) inserted (14.12.2016) by The Misuse of Drugs Act 1971 (Amendment) Order 2016 (S.I. 2016/1109), arts. 1, 4

F96Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(vi)

F97Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(vi)

F98Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(vii)

F99Word in Sch. 2 Pt. 3 para. 1(b) inserted (1.7.2003) by The Misuse of Drugs Act 1971 (Modification) Order 2003 (S.I. 2003/1243), arts. 1, 2(4)(b)

F101Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(ix)

F102Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(ix)

F103Word in Sch. 2 Pt. 3 para. 1(b) inserted (13.6.2012) by The Misuse of Drugs Act 1971 (Amendment) Order 2012 (S.I.2012/1390), art. 3(b)

F104Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(x)

F105Word in Sch. 2 Pt. 3 para. 1(b) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(b)(xi)

F107Words in Sch. 2 Pt. 3 para. 1(d) repealed (26.1.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), art. 2(3)(b)

F108Word in Sch. 2 Pt. 3 para. 1(e) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(d)

F109Word in Sch. 2 Pt. 3 para. 1(e) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(3)(d)

2Any stereoisomeric form of a substance for the time being specified in paragraph 1 of this Part of this Schedule [F110not being phenylpropanolamine.]E+W+S+N.I.

Annotations: Help about Annotation
Close

Annotations are used to give authority for changes and other effects on the legislation you are viewing and to convey editorial information. They appear at the foot of the relevant provision or under the associated heading. Annotations are categorised by annotation type, such as F-notes for textual amendments and I-notes for commencement information (a full list can be found in the Editorial Practice Guide). Each annotation is identified by a sequential reference number. For F-notes, M-notes and X-notes, the number also appears in bold superscript at the relevant location in the text. All annotations contain links to the affecting legislation.

Amendments (Textual)

3Any salt of a substance for the time being specified in paragraph 1 or 2 of this Part of this Schedule.E+W+S+N.I.

4Any preparation or other product containing a substance for the time being specified in any of paragraphs 1 to 3 of this Part of this Schedule.E+W+S+N.I.

Part IVE+W+S+N.I. Meaning of certain Expressions used in this Schedule

For the purposes of this Schedule the following expressions (which are not among those defined in section 37(1) of this Act) have the meanings hereby assigned to them respectively, that is to say—

  • cannabinol derivatives” means the following substances, except where contained in cannabis or cannabis resin, namely tetrahydro derivatives of cannabinol and 3-alkyl homologues of cannabinol or of its tetrahydro derivatives;

  • coca leaf” means the leaf of any plant of the genusErythroxylonfrom whose leaves cocaine can be extracted either directly or by chemical transformation;

  • concentrate of poppy-straw” means the material produced when poppy-straw has entered into a process for the concentration of its alkaloids;

  • [F111“khat” means the leaves, stems or shoots of the plant of the species Catha edulis;]

  • medicinal opium” means raw opium which has undergone the process necessary to adapt it for medicinal use in accordance with the requirements of the British Pharmacopoeia, whether it is in the form of powder or is granulated or is in any other form, and whether it is or is not mixed with neutral substances;

  • opium poppy” means the plant of the speciesPapaver somniferum L;

  • poppy straw” means all parts, except the seeds, of the opium poppy, after mowing;

  • raw opium” includes powdered or granulated opium but does not include medicinal opium.

Annotations: Help about Annotation
Close

Annotations are used to give authority for changes and other effects on the legislation you are viewing and to convey editorial information. They appear at the foot of the relevant provision or under the associated heading. Annotations are categorised by annotation type, such as F-notes for textual amendments and I-notes for commencement information (a full list can be found in the Editorial Practice Guide). Each annotation is identified by a sequential reference number. For F-notes, M-notes and X-notes, the number also appears in bold superscript at the relevant location in the text. All annotations contain links to the affecting legislation.

Amendments (Textual)

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As Enacted or Made):The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as enacted version that was used for the print copy
  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as enacted version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources